BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 15502602)

  • 1. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
    BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin).
    Weiss M; Wasdell M; Patin J
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1415-21. PubMed ID: 15502601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
    Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
    Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
    Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
    J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M; Mao AR; Doyle RL
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder.
    Kent JD; Blader JC; Koplewicz HS; Abikoff H; Foley CA
    Pediatrics; 1995 Aug; 96(2 Pt 1):320-5. PubMed ID: 7630692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
    Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
    J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response.
    Pearson DA; Lane DM; Santos CW; Casat CD; Jerger SW; Loveland KA; Faria LP; Mansour R; Henderson JA; Payne CD; Roache JD; Lachar D; Cleveland LA
    J Am Acad Child Adolesc Psychiatry; 2004 Jun; 43(6):686-98. PubMed ID: 15167085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD.
    Pearson DA; Santos CW; Casat CD; Lane DM; Jerger SW; Roache JD; Loveland KA; Lachar D; Faria LP; Payne CD; Cleveland LA
    J Am Acad Child Adolesc Psychiatry; 2004 Jun; 43(6):677-85. PubMed ID: 15167084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?
    Markowitz JS; Patrick KS
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S54-61. PubMed ID: 18480678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
    Teo SK; Scheffler MR; Wu A; Stirling DI; Thomas SD; Stypinski D; Khetani VD
    J Clin Pharmacol; 2004 Feb; 44(2):173-8. PubMed ID: 14747426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicokinetic assessment of methylphenidate (Ritalin) enantiomers in pregnant rats and rabbits.
    Bakhtiar R; Tse FL
    Biomed Chromatogr; 2004 Jun; 18(5):275-81. PubMed ID: 15236434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
    Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
    J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.